CPHI — China Pharma Holdings, Inc.
Is CPHI overbought or oversold? Here is the current MarketMoodz read.
China Pharma Holdings, Inc. (CPHI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $0.48. The rating moved from Neutral to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.48
- Last changeMoved from Neutral to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
China Pharma Holdings, Inc. shows characteristics typical of microcap, low‑liquidity healthcare issuers: sparse public disclosure, limited analyst and social coverage, and high operational and financing risk. Sector flows currently favor large-cap, M&A-active pharmaceutical names and specialty distributors, offering little obvious near-term catalyst for this issuer. Absent timely audited filings, clear revenue visibility, or a material positive corporate development (e.g., a strategic partnership, credible clinical readout or transparent financing), downside volatility and dilution risk are the dominant near-term scenarios. A positive reversal would require renewed transparency, credible operational milestones, or a financing structure that minimizes shareholder dilution.
Key factors
- No recent EDGAR/financial filing visibility; financial health and revenue trends are unclear
- Penny-stock price and likely low market capitalization imply limited liquidity and high volatility
- Sector themes favor large-cap, M&A-active pharma and specialty distributors rather than microcap Chinese issuers
- Limited social/research coverage and absent analyst attention reduce likelihood of near-term constructive flows
- Potential for dilution or financing need typical for small-cap pharma/healthcare issuers
- Exposure to China-specific regulatory, currency and supply-chain risks
Risks
- Material lack of disclosure or delayed/absent SEC filings creating information asymmetry
- High dilution risk from equity raises, convertible financings or related-party transactions
- Low liquidity and pump-and-dump / manipulation risk common in sub-$1 names
- Regulatory scrutiny or adverse actions in China impacting operations or market access
- Counterparty, manufacturing or supply-chain disruptions for any outsourced production
- Potential for trading suspension or delisting if reporting standards are not met
- Adverse news or litigation that could rapidly depress share value
- Currency volatility and geopolitical tensions affecting investor appetite for China-exposed microcaps
See today's live rating, score and targets
Members see the live hourly rating for CPHI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.